Form 4: WEST PHARMACEUTICAL CEO Green Reports Stock Acquisitions

WEST PHARMACEUTICAL SERVICES INC's President, CEO, and Board Chair, Eric Mark Green, reported the acquisition of common stock through PSU vesting and RSU conversion, alongside related tax-driven dispositions.

Summary

• Eric Mark Green, President, CEO, and Board Chair of WEST PHARMACEUTICAL SERVICES INC, reported multiple transactions involving the company's common stock.
• On February 17, 2026, Green acquired 4,418.771 shares of common stock resulting from the vesting of performance stock units (PSUs) for the 2023-2025 performance period.
• On the same date, 1,305.382 shares were disposed of at $243.19, likely for tax withholding purposes.
• On February 18, 2026, Green acquired 1,318.81 shares of common stock through the conversion of restricted stock units (RSUs).
• Concurrently, 573.551 shares were disposed of at $248.26, also likely for tax withholding.
• Following these transactions, Green directly beneficially owns 175,160.6588 shares of common stock and indirectly owns 257.375 shares through a Non-Qualified Deferred Compensation Plan.
• The RSU conversion on February 18, 2026, represents a portion of a 5,256 RSU grant from February 18, 2025, which vests in four equal annual installments.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive routine filing, reflecting the successful vesting of executive equity compensation, which aligns management's interests with shareholders and indicates the achievement of performance targets.

Positives

• Acquisition of 4,418.771 shares from vested Performance Stock Units (PSUs) indicates successful achievement of performance targets for the 2023-2025 period.
• Acquisition of 1,318.81 shares from vested Restricted Stock Units (RSUs) demonstrates ongoing long-term incentive compensation vesting.
• Increased direct beneficial ownership of common stock to 175,160.6588 shares, aligning management's interests with shareholders.

Negatives

• Disposition of 1,305.382 shares at $243.19 and 573.551 shares at $248.26, likely for tax withholding, reduces the total number of shares held by the executive.

Future Outlook

The filing indicates future vesting events for the remaining 3,956.409 restricted stock units, which were part of a grant on February 18, 2025, and are scheduled to vest in three more equal annual installments.

Industry Context

StockSavvy.ai notes that executive stock acquisitions through vesting of performance and restricted stock units are standard practice in executive compensation across various industries, aligning management incentives with long-term shareholder value. The reported transactions reflect the routine execution of pre-established compensation plans.

Comparison to Industry Standards

• StockSavvy.ai observes that the vesting of PSUs and RSUs is a common component of executive compensation packages in publicly traded companies, particularly in the pharmaceutical services sector.
• Companies like Thermo Fisher Scientific (TMO) and Danaher Corporation (DHR) also utilize similar equity-based incentive programs to retain key executives and link their compensation to company performance and stock appreciation.
• The structure of vesting over multiple years, as seen with the RSU grant, is a standard mechanism to encourage long-term commitment and performance, comparable to practices at leading industry peers.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholders due to continued equity ownership.
• Employees: Routine executive compensation vesting may signal stability in leadership and compensation practices.

Next Steps

• Future annual installments of the 5,256 restricted stock units granted on February 18, 2025, are expected to vest over the next three years.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation transactions (vesting and tax-related dispositions) and does not contain new material information that would fundamentally alter the investment thesis for WEST PHARMACEUTICAL SERVICES INC. It confirms the ongoing execution of established compensation plans and the executive's continued significant ownership, which is generally a positive for alignment but not a catalyst for a 'buy' or 'sell' recommendation based solely on this filing. Therefore, a 'hold' recommendation is appropriate as this is a non-event for stock price movement.

Keywords

WEST PHARMACEUTICAL SERVICES INC, WST, Eric Mark Green, Form 4, Insider Trading, Stock Acquisition, PSU Vesting, RSU Conversion, Common Stock, Executive Compensation, Beneficial Ownership